nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—urinary bladder cancer	0.737	1	CbGaD
Tapentadol—UGT2B7—Epirubicin—urinary bladder cancer	0.0657	0.719	CbGbCtD
Tapentadol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0108	0.119	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—urinary bladder cancer	0.0092	0.101	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—urinary bladder cancer	0.00564	0.0617	CbGbCtD
Tapentadol—CYP2C19—urine—urinary bladder cancer	0.00188	0.132	CbGeAlD
Tapentadol—UGT2B7—prostate gland—urinary bladder cancer	0.00147	0.103	CbGeAlD
Tapentadol—CYP2C9—urine—urinary bladder cancer	0.00146	0.103	CbGeAlD
Tapentadol—OPRK1—prostate gland—urinary bladder cancer	0.00138	0.0969	CbGeAlD
Tapentadol—UGT1A9—renal system—urinary bladder cancer	0.00124	0.0872	CbGeAlD
Tapentadol—CYP2D6—urine—urinary bladder cancer	0.0011	0.077	CbGeAlD
Tapentadol—UGT2B7—renal system—urinary bladder cancer	0.001	0.0703	CbGeAlD
Tapentadol—OPRD1—renal system—urinary bladder cancer	0.000981	0.0689	CbGeAlD
Tapentadol—UGT2B7—female reproductive system—urinary bladder cancer	0.000801	0.0563	CbGeAlD
Tapentadol—OPRK1—female reproductive system—urinary bladder cancer	0.000753	0.0529	CbGeAlD
Tapentadol—SLC6A4—female reproductive system—urinary bladder cancer	0.000446	0.0313	CbGeAlD
Tapentadol—SLC6A2—female reproductive system—urinary bladder cancer	0.000392	0.0276	CbGeAlD
Tapentadol—CYP2C19—vagina—urinary bladder cancer	0.000334	0.0235	CbGeAlD
Tapentadol—CYP2C9—female reproductive system—urinary bladder cancer	0.000286	0.0201	CbGeAlD
Tapentadol—CYP2D6—renal system—urinary bladder cancer	0.000268	0.0188	CbGeAlD
Tapentadol—SLC6A2—lymph node—urinary bladder cancer	0.00023	0.0161	CbGeAlD
Tapentadol—CYP2D6—female reproductive system—urinary bladder cancer	0.000215	0.0151	CbGeAlD
Tapentadol—Ataxia—Doxorubicin—urinary bladder cancer	0.000169	0.00176	CcSEcCtD
Tapentadol—Pruritus—Thiotepa—urinary bladder cancer	0.000168	0.00174	CcSEcCtD
Tapentadol—Paraesthesia—Cisplatin—urinary bladder cancer	0.000167	0.00174	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000167	0.00173	CcSEcCtD
Tapentadol—Tachycardia—Etoposide—urinary bladder cancer	0.000166	0.00173	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000166	0.00172	CcSEcCtD
Tapentadol—Skin disorder—Etoposide—urinary bladder cancer	0.000165	0.00172	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000165	0.00172	CcSEcCtD
Tapentadol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000164	0.00171	CcSEcCtD
Tapentadol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000164	0.00171	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—urinary bladder cancer	0.000162	0.00169	CcSEcCtD
Tapentadol—Diarrhoea—Thiotepa—urinary bladder cancer	0.000162	0.00169	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000162	0.00168	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—urinary bladder cancer	0.000161	0.00168	CcSEcCtD
Tapentadol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000161	0.00168	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000161	0.00167	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00016	0.00167	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—urinary bladder cancer	0.00016	0.00166	CcSEcCtD
Tapentadol—Infestation—Methotrexate—urinary bladder cancer	0.00016	0.00166	CcSEcCtD
Tapentadol—Depression—Methotrexate—urinary bladder cancer	0.000159	0.00166	CcSEcCtD
Tapentadol—Hypotension—Etoposide—urinary bladder cancer	0.000159	0.00166	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000158	0.00165	CcSEcCtD
Tapentadol—Dizziness—Thiotepa—urinary bladder cancer	0.000157	0.00163	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000156	0.00162	CcSEcCtD
Tapentadol—Urticaria—Fluorouracil—urinary bladder cancer	0.000156	0.00162	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—urinary bladder cancer	0.000155	0.00161	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000153	0.00159	CcSEcCtD
Tapentadol—Paraesthesia—Etoposide—urinary bladder cancer	0.000153	0.00159	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—urinary bladder cancer	0.000152	0.00158	CcSEcCtD
Tapentadol—Dyspnoea—Etoposide—urinary bladder cancer	0.000152	0.00158	CcSEcCtD
Tapentadol—Somnolence—Etoposide—urinary bladder cancer	0.000151	0.00157	CcSEcCtD
Tapentadol—Vomiting—Thiotepa—urinary bladder cancer	0.000151	0.00157	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—urinary bladder cancer	0.00015	0.00156	CcSEcCtD
Tapentadol—Infestation—Epirubicin—urinary bladder cancer	0.00015	0.00156	CcSEcCtD
Tapentadol—Rash—Thiotepa—urinary bladder cancer	0.000149	0.00155	CcSEcCtD
Tapentadol—Dermatitis—Thiotepa—urinary bladder cancer	0.000149	0.00155	CcSEcCtD
Tapentadol—Headache—Thiotepa—urinary bladder cancer	0.000148	0.00154	CcSEcCtD
Tapentadol—Decreased appetite—Etoposide—urinary bladder cancer	0.000148	0.00154	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000147	0.00153	CcSEcCtD
Tapentadol—Fatigue—Etoposide—urinary bladder cancer	0.000147	0.00153	CcSEcCtD
Tapentadol—Constipation—Etoposide—urinary bladder cancer	0.000146	0.00151	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000145	0.00151	CcSEcCtD
Tapentadol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000144	0.0015	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000144	0.0015	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000143	0.00149	CcSEcCtD
Tapentadol—Asthenia—Gemcitabine—urinary bladder cancer	0.000143	0.00149	CcSEcCtD
Tapentadol—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000142	0.00147	CcSEcCtD
Tapentadol—Pruritus—Gemcitabine—urinary bladder cancer	0.000141	0.00147	CcSEcCtD
Tapentadol—Nausea—Thiotepa—urinary bladder cancer	0.000141	0.00146	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—urinary bladder cancer	0.000141	0.00146	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—urinary bladder cancer	0.00014	0.00146	CcSEcCtD
Tapentadol—Feeling abnormal—Etoposide—urinary bladder cancer	0.00014	0.00146	CcSEcCtD
Tapentadol—Pruritus—Fluorouracil—urinary bladder cancer	0.000139	0.00144	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000138	0.00144	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—urinary bladder cancer	0.000138	0.00144	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—urinary bladder cancer	0.000138	0.00144	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000137	0.00142	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—urinary bladder cancer	0.000137	0.00142	CcSEcCtD
Tapentadol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000136	0.00142	CcSEcCtD
Tapentadol—Urticaria—Etoposide—urinary bladder cancer	0.000135	0.00141	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000135	0.0014	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—urinary bladder cancer	0.000134	0.0014	CcSEcCtD
Tapentadol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000134	0.0014	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000134	0.00139	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—urinary bladder cancer	0.000133	0.00139	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000133	0.00139	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000133	0.00138	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000132	0.00137	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—urinary bladder cancer	0.000132	0.00137	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—urinary bladder cancer	0.00013	0.00135	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—urinary bladder cancer	0.00013	0.00135	CcSEcCtD
Tapentadol—Dizziness—Fluorouracil—urinary bladder cancer	0.00013	0.00135	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—urinary bladder cancer	0.000129	0.00135	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000129	0.00135	CcSEcCtD
Tapentadol—Chills—Methotrexate—urinary bladder cancer	0.000129	0.00134	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000127	0.00132	CcSEcCtD
Tapentadol—Vomiting—Gemcitabine—urinary bladder cancer	0.000127	0.00132	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—urinary bladder cancer	0.000126	0.00132	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—urinary bladder cancer	0.000126	0.00131	CcSEcCtD
Tapentadol—Rash—Gemcitabine—urinary bladder cancer	0.000126	0.00131	CcSEcCtD
Tapentadol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000126	0.00131	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—urinary bladder cancer	0.000125	0.00131	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000125	0.0013	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—urinary bladder cancer	0.000125	0.0013	CcSEcCtD
Tapentadol—Headache—Gemcitabine—urinary bladder cancer	0.000125	0.0013	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000125	0.0013	CcSEcCtD
Tapentadol—Vomiting—Fluorouracil—urinary bladder cancer	0.000125	0.0013	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000124	0.00129	CcSEcCtD
Tapentadol—Rash—Fluorouracil—urinary bladder cancer	0.000124	0.00129	CcSEcCtD
Tapentadol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000123	0.00128	CcSEcCtD
Tapentadol—Headache—Fluorouracil—urinary bladder cancer	0.000123	0.00128	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000123	0.00128	CcSEcCtD
Tapentadol—Asthenia—Etoposide—urinary bladder cancer	0.000122	0.00127	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000122	0.00127	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—urinary bladder cancer	0.000122	0.00127	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000122	0.00127	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000121	0.00126	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000121	0.00126	CcSEcCtD
Tapentadol—Chills—Epirubicin—urinary bladder cancer	0.00012	0.00125	CcSEcCtD
Tapentadol—Pruritus—Etoposide—urinary bladder cancer	0.00012	0.00125	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—urinary bladder cancer	0.00012	0.00125	CcSEcCtD
Tapentadol—Nausea—Gemcitabine—urinary bladder cancer	0.000118	0.00123	CcSEcCtD
Tapentadol—Vomiting—Cisplatin—urinary bladder cancer	0.000118	0.00123	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—urinary bladder cancer	0.000118	0.00123	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—urinary bladder cancer	0.000118	0.00122	CcSEcCtD
Tapentadol—Rash—Cisplatin—urinary bladder cancer	0.000117	0.00122	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—urinary bladder cancer	0.000117	0.00122	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—urinary bladder cancer	0.000117	0.00122	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—urinary bladder cancer	0.000116	0.00121	CcSEcCtD
Tapentadol—Nausea—Fluorouracil—urinary bladder cancer	0.000116	0.00121	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000116	0.00121	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000115	0.0012	CcSEcCtD
Tapentadol—Tension—Epirubicin—urinary bladder cancer	0.000115	0.00119	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—urinary bladder cancer	0.000114	0.00118	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000113	0.00117	CcSEcCtD
Tapentadol—Dizziness—Etoposide—urinary bladder cancer	0.000113	0.00117	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000112	0.00117	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—urinary bladder cancer	0.000112	0.00117	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000112	0.00117	CcSEcCtD
Tapentadol—Chills—Doxorubicin—urinary bladder cancer	0.000111	0.00116	CcSEcCtD
Tapentadol—Nausea—Cisplatin—urinary bladder cancer	0.00011	0.00115	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—urinary bladder cancer	0.00011	0.00115	CcSEcCtD
Tapentadol—Cough—Methotrexate—urinary bladder cancer	0.000109	0.00113	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000109	0.00113	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—urinary bladder cancer	0.000108	0.00113	CcSEcCtD
Tapentadol—Vomiting—Etoposide—urinary bladder cancer	0.000108	0.00113	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000108	0.00113	CcSEcCtD
Tapentadol—Agitation—Epirubicin—urinary bladder cancer	0.000107	0.00112	CcSEcCtD
Tapentadol—Rash—Etoposide—urinary bladder cancer	0.000107	0.00112	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—urinary bladder cancer	0.000107	0.00112	CcSEcCtD
Tapentadol—Headache—Etoposide—urinary bladder cancer	0.000107	0.00111	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—urinary bladder cancer	0.000106	0.00111	CcSEcCtD
Tapentadol—Tension—Doxorubicin—urinary bladder cancer	0.000106	0.0011	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000106	0.0011	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—urinary bladder cancer	0.000105	0.00109	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—urinary bladder cancer	0.000105	0.00109	CcSEcCtD
Tapentadol—Syncope—Epirubicin—urinary bladder cancer	0.000105	0.00109	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—urinary bladder cancer	0.000103	0.00108	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—urinary bladder cancer	0.000103	0.00107	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000103	0.00107	CcSEcCtD
Tapentadol—Cough—Epirubicin—urinary bladder cancer	0.000102	0.00106	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000102	0.00106	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000102	0.00106	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—urinary bladder cancer	0.000101	0.00105	CcSEcCtD
Tapentadol—Infection—Methotrexate—urinary bladder cancer	0.000101	0.00105	CcSEcCtD
Tapentadol—Nausea—Etoposide—urinary bladder cancer	0.000101	0.00105	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.0001	0.00104	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—urinary bladder cancer	9.95e-05	0.00104	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—urinary bladder cancer	9.94e-05	0.00103	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—urinary bladder cancer	9.92e-05	0.00103	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—urinary bladder cancer	9.9e-05	0.00103	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.88e-05	0.00103	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—urinary bladder cancer	9.85e-05	0.00103	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—urinary bladder cancer	9.73e-05	0.00101	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—urinary bladder cancer	9.72e-05	0.00101	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—urinary bladder cancer	9.7e-05	0.00101	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—urinary bladder cancer	9.62e-05	0.001	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—urinary bladder cancer	9.56e-05	0.000995	CcSEcCtD
Tapentadol—Oedema—Epirubicin—urinary bladder cancer	9.54e-05	0.000993	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.54e-05	0.000993	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—urinary bladder cancer	9.52e-05	0.000991	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—urinary bladder cancer	9.5e-05	0.000989	CcSEcCtD
Tapentadol—Infection—Epirubicin—urinary bladder cancer	9.48e-05	0.000986	CcSEcCtD
Tapentadol—Cough—Doxorubicin—urinary bladder cancer	9.44e-05	0.000982	CcSEcCtD
Tapentadol—Shock—Epirubicin—urinary bladder cancer	9.38e-05	0.000977	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—urinary bladder cancer	9.37e-05	0.000975	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—urinary bladder cancer	9.35e-05	0.000974	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—urinary bladder cancer	9.31e-05	0.000969	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	9.29e-05	0.000967	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—urinary bladder cancer	9.26e-05	0.000964	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.22e-05	0.00096	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—urinary bladder cancer	9.22e-05	0.00096	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—urinary bladder cancer	9.21e-05	0.000958	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—urinary bladder cancer	9.17e-05	0.000955	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—urinary bladder cancer	9.15e-05	0.000953	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.14e-05	0.000952	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—urinary bladder cancer	9.09e-05	0.000946	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—urinary bladder cancer	9.06e-05	0.000943	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—urinary bladder cancer	9e-05	0.000937	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—urinary bladder cancer	8.97e-05	0.000934	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—urinary bladder cancer	8.91e-05	0.000928	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—urinary bladder cancer	8.9e-05	0.000926	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—urinary bladder cancer	8.86e-05	0.000922	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—urinary bladder cancer	8.83e-05	0.000919	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.83e-05	0.000919	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.8e-05	0.000916	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—urinary bladder cancer	8.79e-05	0.000915	CcSEcCtD
Tapentadol—Infection—Doxorubicin—urinary bladder cancer	8.77e-05	0.000913	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.69e-05	0.000905	CcSEcCtD
Tapentadol—Shock—Doxorubicin—urinary bladder cancer	8.68e-05	0.000904	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—urinary bladder cancer	8.66e-05	0.000901	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—urinary bladder cancer	8.63e-05	0.000898	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—urinary bladder cancer	8.61e-05	0.000897	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—urinary bladder cancer	8.57e-05	0.000892	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—urinary bladder cancer	8.56e-05	0.000892	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.53e-05	0.000888	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—urinary bladder cancer	8.5e-05	0.000885	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—urinary bladder cancer	8.48e-05	0.000883	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—urinary bladder cancer	8.4e-05	0.000874	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—urinary bladder cancer	8.4e-05	0.000874	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—urinary bladder cancer	8.29e-05	0.000863	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—urinary bladder cancer	8.25e-05	0.000858	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.23e-05	0.000857	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—urinary bladder cancer	8.22e-05	0.000856	CcSEcCtD
Tapentadol—Constipation—Epirubicin—urinary bladder cancer	8.16e-05	0.000849	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—urinary bladder cancer	8.1e-05	0.000843	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.04e-05	0.000837	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—urinary bladder cancer	7.98e-05	0.000831	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—urinary bladder cancer	7.92e-05	0.000825	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—urinary bladder cancer	7.87e-05	0.000819	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—urinary bladder cancer	7.86e-05	0.000818	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—urinary bladder cancer	7.85e-05	0.000817	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—urinary bladder cancer	7.77e-05	0.000809	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—urinary bladder cancer	7.67e-05	0.000799	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.62e-05	0.000793	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—urinary bladder cancer	7.61e-05	0.000792	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—urinary bladder cancer	7.58e-05	0.000789	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—urinary bladder cancer	7.55e-05	0.000786	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—urinary bladder cancer	7.51e-05	0.000782	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—urinary bladder cancer	7.31e-05	0.000761	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.27e-05	0.000757	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—urinary bladder cancer	7.21e-05	0.000751	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—urinary bladder cancer	7.03e-05	0.000732	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—urinary bladder cancer	7.01e-05	0.00073	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—urinary bladder cancer	6.97e-05	0.000726	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—urinary bladder cancer	6.84e-05	0.000712	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—urinary bladder cancer	6.75e-05	0.000702	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—urinary bladder cancer	6.74e-05	0.000702	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—urinary bladder cancer	6.53e-05	0.000679	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.5e-05	0.000677	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—urinary bladder cancer	6.48e-05	0.000675	CcSEcCtD
Tapentadol—Rash—Methotrexate—urinary bladder cancer	6.43e-05	0.000669	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—urinary bladder cancer	6.42e-05	0.000668	CcSEcCtD
Tapentadol—Headache—Methotrexate—urinary bladder cancer	6.39e-05	0.000665	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—urinary bladder cancer	6.33e-05	0.000659	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—urinary bladder cancer	6.31e-05	0.000657	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—urinary bladder cancer	6.24e-05	0.00065	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—urinary bladder cancer	6.06e-05	0.000631	CcSEcCtD
Tapentadol—Nausea—Methotrexate—urinary bladder cancer	6.05e-05	0.00063	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—urinary bladder cancer	6.04e-05	0.000629	CcSEcCtD
Tapentadol—Rash—Epirubicin—urinary bladder cancer	6.01e-05	0.000626	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—urinary bladder cancer	6.01e-05	0.000625	CcSEcCtD
Tapentadol—Headache—Epirubicin—urinary bladder cancer	5.98e-05	0.000622	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—urinary bladder cancer	5.84e-05	0.000608	CcSEcCtD
Tapentadol—Nausea—Epirubicin—urinary bladder cancer	5.67e-05	0.00059	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—urinary bladder cancer	5.61e-05	0.000584	CcSEcCtD
Tapentadol—Rash—Doxorubicin—urinary bladder cancer	5.56e-05	0.000579	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—urinary bladder cancer	5.56e-05	0.000579	CcSEcCtD
Tapentadol—Headache—Doxorubicin—urinary bladder cancer	5.53e-05	0.000576	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—urinary bladder cancer	5.24e-05	0.000546	CcSEcCtD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	3.81e-05	0.000627	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.59e-05	0.00059	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.51e-05	0.000578	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TYMP—urinary bladder cancer	3.5e-05	0.000576	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HDAC4—urinary bladder cancer	3.42e-05	0.000562	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GLI1—urinary bladder cancer	3.39e-05	0.000557	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—RRM2—urinary bladder cancer	3.37e-05	0.000553	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.36e-05	0.000553	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	3.28e-05	0.00054	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NAT2—urinary bladder cancer	3.17e-05	0.000521	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—HPGDS—urinary bladder cancer	3.12e-05	0.000512	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ENO2—urinary bladder cancer	3.12e-05	0.000512	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.11e-05	0.000512	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.03e-05	0.000498	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTT1—urinary bladder cancer	3.02e-05	0.000497	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2.87e-05	0.000471	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GLI1—urinary bladder cancer	2.86e-05	0.000471	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—RRM2—urinary bladder cancer	2.73e-05	0.00045	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.73e-05	0.000449	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	2.72e-05	0.000447	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAT1—urinary bladder cancer	2.72e-05	0.000447	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.67e-05	0.00044	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RBX1—urinary bladder cancer	2.65e-05	0.000436	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.64e-05	0.000434	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.61e-05	0.00043	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ENO2—urinary bladder cancer	2.53e-05	0.000416	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	2.53e-05	0.000416	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.52e-05	0.000414	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NQO1—urinary bladder cancer	2.51e-05	0.000413	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.5e-05	0.000411	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.5e-05	0.000411	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TSC1—urinary bladder cancer	2.49e-05	0.00041	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	2.49e-05	0.000409	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.48e-05	0.000407	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.48e-05	0.000407	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	2.46e-05	0.000404	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.44e-05	0.000401	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.42e-05	0.000398	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.4e-05	0.000394	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JAG1—urinary bladder cancer	2.37e-05	0.00039	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RBX1—urinary bladder cancer	2.32e-05	0.000382	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.31e-05	0.000379	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.29e-05	0.000376	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.27e-05	0.000373	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	2.24e-05	0.000368	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TSC1—urinary bladder cancer	2.18e-05	0.000359	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	2.11e-05	0.000348	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	2.1e-05	0.000345	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JAG1—urinary bladder cancer	2.08e-05	0.000342	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.06e-05	0.000339	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.06e-05	0.000338	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NQO1—urinary bladder cancer	2.04e-05	0.000336	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.04e-05	0.000336	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—RHOA—urinary bladder cancer	2e-05	0.00033	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.98e-05	0.000326	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RBX1—urinary bladder cancer	1.96e-05	0.000323	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TYMS—urinary bladder cancer	1.95e-05	0.00032	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.94e-05	0.00032	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.93e-05	0.000317	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	1.93e-05	0.000317	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	1.93e-05	0.000317	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—S100B—urinary bladder cancer	1.92e-05	0.000316	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.89e-05	0.000311	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.88e-05	0.000309	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TSC1—urinary bladder cancer	1.85e-05	0.000304	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GPX1—urinary bladder cancer	1.84e-05	0.000303	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—RHOA—urinary bladder cancer	1.82e-05	0.000299	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	1.81e-05	0.000298	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.76e-05	0.000289	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.76e-05	0.000289	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JAG1—urinary bladder cancer	1.76e-05	0.000289	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.73e-05	0.000284	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NCOR1—urinary bladder cancer	1.73e-05	0.000284	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.7e-05	0.00028	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	1.7e-05	0.00028	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—S100B—urinary bladder cancer	1.68e-05	0.000277	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL2—urinary bladder cancer	1.68e-05	0.000277	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.65e-05	0.000272	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.65e-05	0.000271	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.65e-05	0.000271	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.6e-05	0.000263	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RHOA—urinary bladder cancer	1.6e-05	0.000262	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TYMS—urinary bladder cancer	1.58e-05	0.00026	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.58e-05	0.00026	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	1.56e-05	0.000257	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	1.56e-05	0.000257	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.54e-05	0.000254	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—urinary bladder cancer	1.53e-05	0.000251	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TERT—urinary bladder cancer	1.52e-05	0.00025	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.51e-05	0.000249	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NCOR1—urinary bladder cancer	1.51e-05	0.000249	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.51e-05	0.000248	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000247	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GPX1—urinary bladder cancer	1.5e-05	0.000246	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.49e-05	0.000245	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.49e-05	0.000244	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—urinary bladder cancer	1.47e-05	0.000242	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	1.47e-05	0.000242	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.44e-05	0.000237	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	1.42e-05	0.000234	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.4e-05	0.00023	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGFR3—urinary bladder cancer	1.4e-05	0.00023	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	1.38e-05	0.000227	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000227	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.37e-05	0.000225	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.36e-05	0.000223	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ESR1—urinary bladder cancer	1.36e-05	0.000223	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.35e-05	0.000222	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—urinary bladder cancer	1.34e-05	0.00022	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TERT—urinary bladder cancer	1.33e-05	0.000219	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	1.33e-05	0.000218	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.3e-05	0.000214	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.29e-05	0.000211	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.28e-05	0.00021	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.25e-05	0.000205	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.22e-05	0.000201	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.19e-05	0.000196	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.19e-05	0.000196	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	1.19e-05	0.000196	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	1.19e-05	0.000195	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.18e-05	0.000195	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.18e-05	0.000195	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.18e-05	0.000194	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	1.17e-05	0.000193	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.17e-05	0.000193	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	1.17e-05	0.000192	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.15e-05	0.00019	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.14e-05	0.000187	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.13e-05	0.000186	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.13e-05	0.000185	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—urinary bladder cancer	1.12e-05	0.000184	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.1e-05	0.000181	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.09e-05	0.00018	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	0.00018	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	0.000178	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.08e-05	0.000177	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	1.08e-05	0.000177	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1.08e-05	0.000177	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.06e-05	0.000175	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	0.000173	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	1.04e-05	0.000171	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.04e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.03e-05	0.00017	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	1.03e-05	0.000169	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	1.02e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.01e-05	0.000165	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	9.95e-06	0.000164	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	9.67e-06	0.000159	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NQO1—urinary bladder cancer	9.6e-06	0.000158	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—urinary bladder cancer	9.47e-06	0.000156	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	9.44e-06	0.000155	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	9.43e-06	0.000155	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	9.38e-06	0.000154	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.31e-06	0.000153	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—urinary bladder cancer	9.03e-06	0.000148	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	9.02e-06	0.000148	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NQO1—urinary bladder cancer	8.83e-06	0.000145	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	8.82e-06	0.000145	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	8.81e-06	0.000145	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	8.79e-06	0.000145	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NQO1—urinary bladder cancer	8.75e-06	0.000144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	8.73e-06	0.000144	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	8.7e-06	0.000143	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	8.66e-06	0.000142	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	8.54e-06	0.00014	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.51e-06	0.00014	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.49e-06	0.00014	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	8.49e-06	0.00014	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	8.28e-06	0.000136	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	8.22e-06	0.000135	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	8.18e-06	0.000134	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.12e-06	0.000133	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	8.09e-06	0.000133	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	8e-06	0.000132	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.97e-06	0.000131	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	7.91e-06	0.00013	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	7.87e-06	0.000129	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.74e-06	0.000127	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	7.71e-06	0.000127	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—urinary bladder cancer	7.69e-06	0.000126	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	7.49e-06	0.000123	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.46e-06	0.000123	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	7.44e-06	0.000122	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	7.44e-06	0.000122	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.4e-06	0.000122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	7.38e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	7.36e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	7.35e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	7.35e-06	0.000121	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—urinary bladder cancer	7.34e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	7.3e-06	0.00012	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	7.1e-06	0.000117	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.06e-06	0.000116	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	7.05e-06	0.000116	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	7.04e-06	0.000116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	7e-06	0.000115	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.95e-06	0.000114	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	6.91e-06	0.000114	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	6.9e-06	0.000113	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	6.9e-06	0.000113	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.84e-06	0.000113	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.78e-06	0.000112	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.76e-06	0.000111	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.76e-06	0.000111	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.71e-06	0.00011	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.71e-06	0.00011	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	6.69e-06	0.00011	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.52e-06	0.000107	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.52e-06	0.000107	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	6.5e-06	0.000107	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	6.48e-06	0.000107	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	6.42e-06	0.000106	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	6.36e-06	0.000105	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	6.33e-06	0.000104	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	6.3e-06	0.000104	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.3e-06	0.000104	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	6.29e-06	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	6.19e-06	0.000102	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	6.05e-06	9.95e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	6e-06	9.86e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.98e-06	9.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.93e-06	9.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	5.83e-06	9.59e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	5.79e-06	9.53e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	5.72e-06	9.4e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.54e-06	9.11e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	5.27e-06	8.67e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	5.23e-06	8.6e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	5.11e-06	8.41e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	5.08e-06	8.35e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	5.06e-06	8.33e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	4.86e-06	7.99e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.85e-06	7.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.83e-06	7.94e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.81e-06	7.9e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.66e-06	7.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.62e-06	7.59e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	4.29e-06	7.06e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	4.15e-06	6.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	4.11e-06	6.75e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.81e-06	6.27e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.78e-06	6.22e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.62e-06	5.95e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.45e-06	5.67e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.33e-06	5.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.3e-06	5.42e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.17e-06	5.21e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.14e-06	5.17e-05	CbGpPWpGaD
